HomeCompareMTP vs PLD

MTP vs PLD: Dividend Comparison 2026

MTP yields 701.51% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MTP wins by $924932.29M in total portfolio value
10 years
MTP
MTP
● Live price
701.51%
Share price
$0.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$924938.20M
Annual income
$722,372,390,440.71
Full MTP calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — MTP vs PLD

📍 MTP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMTPPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MTP + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MTP pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MTP
Annual income on $10K today (after 15% tax)
$59,628.20/yr
After 10yr DRIP, annual income (after tax)
$614,016,531,874.60/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, MTP beats the other by $614,012,493,758.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MTP + PLD for your $10,000?

MTP: 50%PLD: 50%
100% PLD50/50100% MTP
Portfolio after 10yr
$462472.05M
Annual income
$361,188,570,582.94/yr
Blended yield
78.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

MTP
No analyst data
Altman Z
-17.1
Piotroski
1/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MTP buys
0
PLD buys
0
No recent congressional trades found for MTP or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMTPPLD
Forward yield701.51%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$924938.20M$5.91M
Annual income after 10y$722,372,390,440.71$4,750,725.19
Total dividends collected$908543.22M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: MTP vs PLD ($10,000, DRIP)

YearMTP PortfolioMTP Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$80,851$70,150.82$11,241$540.96+$69.6KMTP
2$616,581$530,070.28$13,019$991.13+$603.6KMTP
3$4,437,682$3,777,940.56$15,801$1,870.97+$4.42MMTP
4$30,160,247$25,411,927.64$20,609$3,701.21+$30.14MMTP
5$193,682,255$161,410,790.66$29,919$7,867.97+$193.65MMTP
6$1,175,972,185$968,732,172.36$50,631$18,617.74+$1175.92MMTP
7$6,755,308,275$5,497,018,037.06$105,528$51,352.20+$6755.20MMTP
8$36,739,695,007$29,511,515,151.87$287,364$174,449.42+$36739.41MMTP
9$189,313,837,689$150,002,364,032.24$1,081,760$774,280.77+$189312.76MMTP
10$924,938,196,768$722,372,390,440.71$5,908,209$4,750,725.19+$924932.29MMTP

MTP vs PLD: Complete Analysis 2026

MTPStock

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Full MTP Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this MTP vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MTP vs SCHDMTP vs JEPIMTP vs OMTP vs KOMTP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.